Jeremy G. Chadwick, Chief Operating Officer at Kymera Therapeutics, Inc. (KYMR), sold 6,551 shares at $90.00 ($590K) on 2026-04-14, disclosed to the SEC on 2026-04-16.
Scheduled sale ($590k) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $90.00 | 5,251 | $473K | 80.2% |
| 2 | $90.00 | 1,300 | $117K | 19.8% |
| Total | $90.00 avg | 6,551 | $590K | 100% |
| Filing → |
| KYMR | SELL | 2026-04-01 | $1.9M | — | Filing → |
| KYMR | SELL | 2026-03-25 | $18.0M | — | Filing → |
| KYMR | SELL | 2026-03-11 | $4.3M | — | Filing → |